Editorial intelligence for pharma strategy
Definition and regulatory context for Prescription Drug User Fee Act (PDUFA) action dates in FDA review.
This is a verified reference page — not a flagship Humanexa Review essay. Claims are sourced from structured evidence and updated on a reference schedule.
A PDUFA date is the user fee goal date by which the FDA commits to complete review of a marketing application for a prescription drug, established under the Prescription Drug User Fee Act (PDUFA). It represents a target action window—approval, complete response letter, or other regulatory action—not a guaranteed approval date.
PDUFA dates coordinate regulatory, commercial, and capital markets planning. Companies disclose expected action dates in SEC filings; investors treat them as catalysts while recognizing that FDA may act early or issue complete response letters. Understanding PDUFA mechanics helps separate regulatory process from clinical merit.
When a biopharmaceutical company submits a New Drug Application or Biologics License Application, FDA assigns a PDUFA goal date. Corporate 8-K filings often announce acceptance and the action date. Portfolio teams map PDUFA calendars alongside patent expiries and competitive launches.